Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer patients may prefer a quick shot over a long IV

NCT ID NCT05171777

Symptom relief Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether people with non-small cell lung cancer prefer getting the drug atezolizumab as a shot under the skin (subcutaneous) or through an IV drip. About 179 patients tried both methods and reported which they liked better. The goal was to see if the shot is more convenient and preferred by patients and healthcare providers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atezolizumab (Tecentriq)
What this could lead to
If successful, this could show that a subcutaneous injection is preferred over an IV infusion, making treatment more convenient for patients.
What could go wrong
This is a Phase 2 preference study, not a test of effectiveness. The results may not change how well the drug works or apply to all lung cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

179 people

The number who actually took part.

Started

Apr 2022

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for All Participants: * ECOG performance status of 0 or 1 Inclusion Criteria for Participants with Early-stage NSCLC: * Participants must have a complete resection of a histologically or cytologically confirmed Stage II, IIIA, and selected IIIB (T3-N2) NSCLC * PD-L1 expression TC ≥ 1% or TPS ≥ 1% * Participants must have completed adjuvant chemotherapy at least 4 weeks and up to 12 weeks prior to randomization and must be adequately recovered from chemotherapy. For participants in the adjuvant setting, neoadjuvant chemotherapy or chemoradiotherapy is acceptable provided that participants also received adjuvant chemotherapy as per protocol's requirement. Inclusion Criteria for Participants with Stage IV NSCLC: * Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC * Life expectancy ≥ 18 weeks in the opinion of the investigator * PD-L1 expression TC ≥ 50% or TPS ≥ 50% or TC3 or IC3 * No prior systemic treatment for Stage IV non-squamous or squamous NSCLC * Participants who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from randomization since the last chemotherapy, radiotherapy, or chemoradiotherapy cycle. Exclusion Criteria for All Participants: * History of malignancy within 5 years prior to initiation of study treatment, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death * Uncontrolled tumor-related pain * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures * Participants known to have a sensitizing mutation in the EGFR gene or an ALK fusion oncogene * History of leptomeningeal disease * Uncontrolled or symptomatic hypercalcemia * Active or history of autoimmune disease or immune deficiency * History of idiopathic pulmonary fibrosis, organizing pneumonia), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan * Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina Exclusion Criteria for Participants with Stage IV NSCLC: * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • A.O.U. Maggiore della Carità

    Novara, Piedmont, 28100, Italy

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Asante Rogue Regional Medical Center

    Medford, Oregon, 97504-8332, United States

  • Azienda Ospedaliera Universitaria Senese

    Siena, Abruzzo, 53100, Italy

  • CEMIC

    Buenos Aires, C1431FWN, Argentina

  • Centro Oncologico Korben

    Ciudad Autonoma Buenos Aires, C1426AGE, Argentina

  • Chungbuk National University Hospital

    Cheongju-si, 28644, South Korea

  • Clinica CIMCA

    San José, 10103, Costa Rica

  • Complejo Hospitalario Universitario A Coruña (CHUAC)

    A Coruña, LA Coruna, 15006, Spain

  • Fundación CENIT para la Investigación en Neurociencias

    Buenos Aires, C1125ABD, Argentina

  • Hospital Clinico Universitario Lozano Blesa

    Zaragoza, 50009, Spain

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario de Canarias

    San Cristóbal de La Laguna, Tenerife, 38320, Spain

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08041, Spain

  • ICIMED Instituto de Investigación en Ciencias Médicas

    San José, 10108, Costa Rica

  • IRCCS Istituto Regina Elena (IFO)

    Rome, Lazio, 00144, Italy

  • Instituto Europeo di Oncologia

    Milan, Lombardy, 20141, Italy

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, 01246-000, Brazil

  • Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy

    Otwock, 05-400, Poland

  • New Jersey Hematology Oncology Associates LLC

    Brick, New Jersey, 08724-3009, United States

  • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda

    Ijuí, Rio Grande do Sul, 98700-000, Brazil

  • OrlandiOncología

    Santiago, 7500713, Chile

  • Oulun yliopistollinen sairaala (OYS)

    Oulu, 90220, Finland

  • Pauls Stradins Clinical University Hospital

    R?ga, LV-1002, Latvia

  • Riga East Clinical University Hospital Latvian Oncology Centre

    Riga, LV-1079, Latvia

  • Royal Victoria Regional Health Centre

    Barrie, Ontario, L4M 6M2, Canada

  • Sault Area Hospital

    Sault Ste. Marie, Ontario, P6B 0A8, Canada

  • Tampereen yliopistollinen sairaala (TAYS)

    Tampere, 33521, Finland

  • Tri County Hematologyoncology

    Massillon, Ohio, 44646-9128, United States

  • Turun yliopistollinen keskussairaala (TYKS)

    Turku, 20521, Finland

  • UPMC - Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • Vaasan Keskussairaala

    Vaasa, 65130, Finland

  • Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie

    Olsztyn, 10-357, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.